Extract Or Material Containing Or Obtained From A Micro-organism As Active Ingredient (e.g., Bacteria, Protozoa, Etc.) Patents (Class 424/780)
-
Publication number: 20140105862Abstract: The present invention relates to novel strains of Streptomyces microflavus and methods of their use for controlling diseases or pests of a plant. The invention also relates to a fermentation broth obtained by cultivating a gougerotin producing Streptomyces strain, wherein the fermentation broth contains at least about 1 g/L gougerotin. The invention also relates to a method of producing a fermentation broth of a gougerotin producing Streptomyces strain, wherein the fermentation broth contains at least about 1 g/L gougerotin, the method comprising cultivating the Streptomyces strain in a culture medium containing a digestible carbon source and a digestible nitrogen source under aerobic conditions, wherein the culture medium contains an amino acid at a concentration effective to achieve a gougerotin concentration of at least 1 g/L.Type: ApplicationFiled: October 11, 2013Publication date: April 17, 2014Applicant: Bayer CropScience LPInventors: Brian CAMPBELL, Damian CURTIS, Shaohua GUAN, Magalie GUILHABERT-GOYA, Daniel M. JOO, Tara LU, Jonathan S. MARGOLIS, Reed Nathan ROYALTY, Gerardo Bueno SALAZAR, David SESIN, Frisby Davis SMITH, Colleen TAYLOR, Hong ZHU
-
Patent number: 8697154Abstract: The present invention relates to an extract from bacterial strains, such as Staphylococcus, Moraxella, Klebsiella, Streptococcus, and Haemophilus. The extract is useful as a treatment for indications such as respiratory disorders, compositions comprising the extract, and processes of making the extract from media that do not pose a risk of prion diseases.Type: GrantFiled: March 5, 2008Date of Patent: April 15, 2014Assignee: OM Pharma SAInventors: Jacques Alain Bauer, Marco Salvagni, Jean-Pierre Leon Vigroox, Laetitia Chalvet, Carlo Chiavaroli
-
Patent number: 8697155Abstract: This disclosure provides a method of treating obesity and related disorders through the administration of a composition comprising a neurotoxin and a mucosal permeabilizing agent. Methods for making and using the described compositions are also provided.Type: GrantFiled: July 20, 2009Date of Patent: April 15, 2014Assignee: Mayo Foundation for Medical Education and ResearchInventors: Michael J. Levy, Mark D. Topazian, Steven P. Petrou
-
Patent number: 8691301Abstract: A self gassing composition comprising at least one surfactant and a fermentation base including a gas producing organism and at least one sugar is disclosed. Use of a nonionic surfactant in the self gassing composition allows the fermentation base to continue reacting and producing gas. Additionally, a personal care cleansing product and method for storing and delivering an aqueous composition having at least one surfactant and pressurized gas dissolved therein is disclosed. In one aspect, the composition is stored in an internal reservoir in a container such that when a sealing device is removed from a valveless opening, the composition foams and plumes out the opening of the container as the gas dissolved in the composition is released. In addition to the self gassing composition, a pressurized gas may be injected into a surfactant composition to produce the gas pressurized cleaning composition.Type: GrantFiled: June 30, 2008Date of Patent: April 8, 2014Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Jeffery Richard Seidling, Scott W. Wenzel, Stacy Averic Mundschau, David W. Koenig
-
Patent number: 8691219Abstract: Chromobacterium subtsugae sp. nov., a new species of the genus Chromobacterium which possesses insecticidal activity, is described. The invention also relates to insecticidally-active metabolites obtained from the strain and to insecticidal compositions comprising cultures of the strain and/or supernatants, filtrates, and extracts obtained from the strain, and use thereof to control insect pests.Type: GrantFiled: February 8, 2007Date of Patent: April 8, 2014Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Phyllis A. W. Martin, Ashaki D. S. Shropshire, Dawn E. Gundersen-Rindal, Michael B. Blackburn
-
Publication number: 20140093554Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to increase bone mineral content and/or bone mass density.Type: ApplicationFiled: June 10, 2013Publication date: April 3, 2014Inventors: Eline Marleen VAN DER BEEK, Gelske SPEELMANS, Antonie VAN BAALEN, Annemarie OOSTING, Günther BOEHM
-
Publication number: 20140086849Abstract: The present invention relates to combination therapies for the treatment of a variety of disorders in mammals, including hepatic disorders and cancer. The combination of agents includes naturally-occurring (versus synthetic) oligonucleotides, particularly immunostimulatory oligodeoxynucleotides such as CpG ODNs, obtained from a natural source and one or more extracts from a Gram positive bacteria, such as Lactobacillus spp.Type: ApplicationFiled: September 23, 2013Publication date: March 27, 2014Inventor: Elizabeth McKenna
-
Publication number: 20140086880Abstract: The present invention is directed to a filamentous bacteriophage for use in treating a neurodegenerative tauopathy or susceptibility to a neurodegenerative tauopathy and a method of using the bacteriophage for reducing the formation of fibrils of tau protein or for disaggregating pre-formed fibrils of tau protein, such as in a patient suffering from neurodegenerative tauopathy. The filamentous bacteriophage used in the present invention does not display (i) a mammalian cell internalization signal (ii) a ?-amyloid antigen or an antibody to ?-amyloid, or (iii) a tau protein antigen or an antibody to tau protein.Type: ApplicationFiled: March 12, 2012Publication date: March 27, 2014Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.Inventor: Beka Solomon
-
Patent number: 8673324Abstract: The embodiment of invention provides a method for producing ?-aminobutyric acid, including the steps of providing a medium including Saccharomyces cerevisiae, adding an extract of Rhinacanthus nasutus into the medium and fermentating Saccharomyces cerevisiae in the medium added with the extract of Rhinacanthus nasutus to produce ?-aminobutyric acid.Type: GrantFiled: January 19, 2012Date of Patent: March 18, 2014Assignee: Industrial Technology Research InstituteInventors: Ching-Hui Chang, Tsai-Mei Wu
-
Patent number: 8673616Abstract: The present invention relates to a novel wild-type Lactococcus lactis subsp. cremoris bacteria strain with increased vitamin K2 production and mutants and variants thereof and methods for preparation of a fermented food or feed product enriched in vitamin K2 and a vitamin K enriched edible product for amelioration and/or prevention of vitamin K deficiency. The present invention also relates to the fermented food or feed product and the edible product obtainable by the methods herein and to the wild-type Lactococcus lactis subsp. cremoris bacteria strain for use in treatment and/or prevention of vitamin K deficiency in a mammal, such as a human.Type: GrantFiled: August 11, 2011Date of Patent: March 18, 2014Assignee: CHR. Hansen A/SInventors: Christel Garrigues, Martin Bastian Pedersen
-
Publication number: 20140073501Abstract: A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.Type: ApplicationFiled: March 15, 2013Publication date: March 13, 2014Inventors: Ratnakar Asolkar, Marja Koivunen, Pamela Marrone
-
Publication number: 20140065209Abstract: The present invention relates to a probiotic bacteria, and/or soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria for use in the treatment of a disorder associated with Tight Junction function, characterised in that the probiotic bacteria, soluble metabolite of a probiotic bacteria and/or a cell lysate of a probiotic bacteria is formulated for topical administration.Type: ApplicationFiled: May 2, 2012Publication date: March 6, 2014Applicant: DUPONT NUTRITION BIOSCIENCES APSInventors: Heli Putaala, Arthur Ouwehand, Kirsti Tiihonen, Nina Rautonen
-
Publication number: 20140065218Abstract: The invention describes a microorganism of the order of lactic acid bacteria or an analogue, fragment, derivative, mutant or combination thereof, wherein the microorganism, or analogue, fragment, derivative, mutant or combination thereof can coaggregate with Streptococcus pyogenes.Type: ApplicationFiled: May 16, 2012Publication date: March 6, 2014Applicant: ORGANOBALANCE MEDICAL AGInventors: Christine Lang, Andreas Raab, Natalia Bolotina
-
Publication number: 20140056853Abstract: Provided is a method for modulating soybean cyst nematode infestation of a plant comprising applying to the plant an effective amount of a composition comprising a Chromobacterium, Burkholderia, and/or Flavobacterium strain to modulate the soybean cyst nematode infestation. The composition may be applied directly to the seed or in a substrate for growing the plant, such as in the soil.Type: ApplicationFiled: November 5, 2013Publication date: February 27, 2014Applicant: Marrone Bio Innovations, Inc.Inventors: Pamela Marrone, Timothy B. Johnson, Hai Su, Lijuan Xing, Phyllis Himmel
-
Patent number: 8642098Abstract: The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition.Type: GrantFiled: February 24, 2011Date of Patent: February 4, 2014Assignee: Thylabisco ABInventors: Per-Åke Albertsson, Charlotte Albertsson-Erlanson
-
Publication number: 20140030369Abstract: Soil amendment compositions and methods for using the same are provided. The subject compositions are aqueous compositions consisting essentially of a carbon-skeleton energy component, a predisposing agent and a vitamin-cofactor component. The subject compositions find use in a variety of soil amendment applications, including: the control of soil born pests and pathogens; the improvement in soil fertility and/or characteristics, e.g. mineral release, water filtration; the neutralization and/or degradation of toxins, etc.Type: ApplicationFiled: December 27, 2012Publication date: January 30, 2014Inventor: Thomas T. Yamashita
-
Publication number: 20140030194Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.Type: ApplicationFiled: January 16, 2013Publication date: January 30, 2014Applicant: Labyrinth Bio, Inc.Inventor: Elizabeth McKenna
-
Publication number: 20140026255Abstract: This invention relates to compositions and methods for reducing reactive oxygen species in plants, yeast, algae or bacteria by transforming a plant, yeast or bacteria with a heterologous polynucleotide encoding a superoxide reductase from an archaeon species. The invention also provides methods for protecting a photosynthetic reaction center, for reducing photorespiration and/or for increasing the photosynthetic efficiency of plants or cyanobacteria as well as methods for increasing tolerance to abiotic stress in plants, yeast or bacteria by transforming a plant, yeast, or bacteria with a heterologous polynucleotide encoding a archaeon superoxide reductase. Methods for delaying senescence, reducing lignin polymerization and increasing accessibility of cell wall cellulose to an enzyme in a plant by transforming the plant with a heterologous polynucleotide encoding an archaeon superoxide reductase are also provided.Type: ApplicationFiled: June 24, 2013Publication date: January 23, 2014Inventors: AMY MICHELE GRUNDEN, HEIKE INGE ADA SEDEROFF, ROOPA D. YALAMANCHILI
-
Publication number: 20140017217Abstract: An object of the present invention is to provide a QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent. Method for Achieving the Object A QOL improving or sustaining agent, a physical health improving or sustaining agent, a vitality improving or sustaining agent, a fatigue recovery or alleviating agent, or an anti-fatigue agent containing Lactobacillus ONRICb0240 (FERM BP-10065).Type: ApplicationFiled: March 28, 2012Publication date: January 16, 2014Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Mina Tsubouchi, Takao Saito, Masamichi Toba, Noriyuki Kouda, Shoji Shinkai
-
Patent number: 8613962Abstract: There is provided a medicinal agent that is effective and highly safe for the prevention or alleviation of a peripheral nerve disorder that develops as a side effect occurring after the administration of an anti-cancer agent. The present invention relates to a novel medical use of an extract from inflamed tissues inoculated with vaccinia virus, and to a prophylactic or alleviating agent for a peripheral nerve disorder that contains the extract as an active ingredient. The agent containing the extract as an active ingredient is used for a prophylactic or alleviating agent for a peripheral nerve disorder induced by an anti-cancer agent and is a highly safe and remarkably highly useful medicinal agent with few side effects.Type: GrantFiled: August 28, 2008Date of Patent: December 24, 2013Assignees: Kyushu University, National University Corporation, Nippon Zoki Pharmaceutical Co., LtdInventors: Ryozo Oishi, Yoshinori Itoh, Nobuaki Egashira
-
Patent number: 8613917Abstract: Current approaches for treating cancer are limited, in part, by the inability of drugs to affect the poorly vascularized regions of tumors. We have found that spores of anaerobic bacteria in combination with agents which interact with microtubules can cause the destruction of both the vascular and avascular compartments of tumors. Two classes of microtubule inhibitors were found to exert markedly different effects. Some agents that inhibited microtubule synthesis, such as vinorelbine, caused rapid, massive hemorrhagic necrosis when used in combination with spores. In contrast, agents that stabilized microtubules, such as the taxane, docetaxel, resulted in slow tumor regressions that killed most neoplastic cells. Remaining cells in the poorly perfused regions of tumors could be eradicated by sporulated bacteria.Type: GrantFiled: August 5, 2011Date of Patent: December 24, 2013Assignee: The Johns Hopkins UniversityInventors: Long Dang, Chetan Bettegowda, Kenneth W. Kinzler, Bert Vogelstein
-
Publication number: 20130338002Abstract: Disclosed are compounds of Formula 1, wherein X is O or S; Y is O or S; and R1, R2, R3 and R4 are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound or a composition of the invention.Type: ApplicationFiled: August 15, 2013Publication date: December 19, 2013Applicant: E I DU PONT DE NEMOURS AND COMPANYInventors: CALEB WILLIAM HOLYOKE, JR., WENWING ZHANG
-
Publication number: 20130336948Abstract: A composition is provided that includes a fish spawn protein isolate. A natural product extract is also present that includes unsaturated fatty acids and sterols. An emulsifier is provided to form a mixture of the isolate and the extract. A composition is also provided that includes an egg hatching protein isolate and at least one biocide protective of isolate activity. An emulsifier forms a mixture with the isolate that has an aqueous phase buffered to a pH of between 5.6 and 7.9. A process of producing such a cosmetic has an emulsion or an aqueous phase that is buffered to a pH of between 5.5 and 7.9 prior to the addition of isolate to the emulsion. A process of improving skin appearance is provided that includes the application of the cosmetic to the skin at least three times per week to achieve the improvement of the skin appearance.Type: ApplicationFiled: August 19, 2013Publication date: December 19, 2013Applicant: Restorsea, LLCInventors: Enrique P. Alabata, Patricia S. Pao
-
Patent number: 8609811Abstract: The present invention relates to variants (mutants) of polypeptides, in particular Termamyl-like alpha-amylases, which variant has alpha-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent alpha-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca2+ dependency, specific activity, and solubility, in particular under production conditions.Type: GrantFiled: September 4, 2008Date of Patent: December 17, 2013Assignee: Novozymes A/SInventors: Carsten Andersen, Torben Vedel Borchert, Bjarne Ronfeldt Nielsen
-
Publication number: 20130323208Abstract: Invention is using M. brumae is a mycobacterium strain which stimulates immune system cells strongly, is non-pathogen for humans and has all of the defining attributes of the strain with catalog number 51384, American Type Culture Collection (ATCC) for therapy of superficial bladder cancers.Type: ApplicationFiled: December 20, 2011Publication date: December 5, 2013Inventors: Naciye Leyla Açan, Abdurrahim Haluk Özen, Esra Büber, Zühtü Tanil Kocagöz, Zeliha Ertürk, Zehra Stara Yüksel, Mehmet Selçuk Keskin, Bagnu Orhan, Alpaslan Alp, Zeynep Saribas
-
Publication number: 20130323215Abstract: The present invention discloses a novel antitumour agent which provides an antitumour activity based on metabolites with reduced side effects. Moreover, the antitumour agent is prepared starting with a highly safe bacterium used in food production, which is a probiotic lactic acid bacterium.Type: ApplicationFiled: November 29, 2010Publication date: December 5, 2013Inventors: Hooi Ling Foo, Teck Chwen Loh, Li Oon Chuah, Noorjahan Banu Alitheen, Raha Abdul Rahim
-
Patent number: 8598116Abstract: The present invention provides methods for the treatment of an ongoing influenza infection by administering a polypeptide to a subject suffering from an influenza infection. The polypeptide consists of SEQ ID NO: 4. The present invention also provides a method of interfering with fusion of an influenza virus envelope with a host cell membrane by contacting the host cell with a polypeptide consisting of SEQ ID NO: 4.Type: GrantFiled: May 29, 2012Date of Patent: December 3, 2013Assignees: The Administrators of the Tulane, Educational Fund and Autoimmune Technologies, LLCInventors: Robert F. Garry, Russell B. Wilson
-
Publication number: 20130316032Abstract: This application provides a substance containing disrupted cells of an anti-inflammatory lactic acid bacterium and having an effect of preventing or improving arthritis in a subject, a composition containing the substance and the preparation method thereof, and a method for enhancing the effect of preventing and improving arthritis with the use of the substance.Type: ApplicationFiled: January 18, 2012Publication date: November 28, 2013Inventors: Kikuji Itoh, Shigeru Fujiwara
-
Publication number: 20130316033Abstract: The present invention relates to a novel bacterial strain isolated from groundwater. The invention also relates to bacterial extracts and to the use of same in the context of the treatment of inflammations. More particularly, the present invention relates to novel compositions of interest in the treatment and the prevention of inflammatory disorders, notably dermatological pathologies.Type: ApplicationFiled: December 22, 2011Publication date: November 28, 2013Applicants: PIERRE FABRE DERMO-COSMETIQUE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6)Inventors: Philippe Lebaron, Muriel Bourrain, Nathalie Castex-Rizzi, Thien Nguyen
-
Publication number: 20130315967Abstract: The present invention provides methods for preventing biofilm formation on a surface. The present invention also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.Type: ApplicationFiled: July 29, 2013Publication date: November 28, 2013Inventor: Cynthia K. BRUNO
-
Patent number: 8591882Abstract: An object of the present invention is to find a novel and useful component in a culture supernatant of a lactic acid bacterium and to provide an effective utilization method of the component. The utilization method is a cytoprotective agent containing, as an active ingredient, a low-molecular-weight fraction in a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.Type: GrantFiled: August 12, 2011Date of Patent: November 26, 2013Assignee: Kabushiki Kaisha Yakult HonshaInventors: Naoki Izawa, Tomoko Kurasawa, Toshiro Sone, Katsuyoshi Chiba
-
Patent number: 8591880Abstract: The present invention relates to supporting weight management, weight loss and/or to the prevention and/or treatment of metabolic disorders. In particular the present invention relates to preventing and/or treating metabolic disorders by modulating, in particular reducing the amount of proteobacteria and/or deferribacteres in the gut. One embodiment of the present invention relates to the use of a primary composition comprising an agent that reduces the amount of proteobacteria, preferably gamma-proteobacteria, even more preferred enterobacteria; and/or deferribacteres in the gut for the preparation of a composition to treat or prevent metabolic disorders, to support weight loss and/or to support weight management.Type: GrantFiled: July 25, 2008Date of Patent: November 26, 2013Assignee: Nestec S.A.Inventors: Chieh Jason Chou, David Philippe, Christian Darlmont, Fabrizio Arigoni, Catherine Mace
-
Publication number: 20130309212Abstract: Provided is a Lactobacillus salivarius belonging to Lactobacillus salivarius subsp. Salivarius and deposited in China General Microbiological Culture Collection Center with an accession number CGMCC No: 3606. Further provided is a method for preparing a metabolite of the Lactobacillus salivarius, wherein the Lactobacillus salivarius is as described above. Further provided is a composition, comprising viable strains of the Lactobacillus salivarius and/or the metabolite of the Lactobacillus salivarius prepared as described above. Further provided is a use of the composition in preparation of drugs for prevention and/or treatment of cancers and a method for treating and/or preventing cancers. The viable strains of Lactobacillus salivarius and the metabolite of Lactobacillus salivarius provided in the present invention can both remove the genotoxicity of 4-NQQ in vivo, thus exerting an effect of effectively preventing and/or treating cancers.Type: ApplicationFiled: January 17, 2012Publication date: November 21, 2013Inventors: Ming Zhang, Fang Wang, Huiyuan Guo, Jun Zhu, Lu Jiang
-
Patent number: 8586090Abstract: This invention provides melanin nanoshells and their use for protection against radiation, particularly ionizing radiation, and electronic pulses, and methods of making materials comprising melanin nanoshells.Type: GrantFiled: April 2, 2007Date of Patent: November 19, 2013Assignee: Albert Einstein College of Medicine of Yeshiva UniversityInventors: Ekaterina Dadachova, Arturo Casadevall
-
Publication number: 20130302297Abstract: The invention relates to the oral or nutraceutical cosmetic use of an effective amount of at least one monounsaturated fatty acid, a salt thereof and/or an ester thereof, as an active agent for treating and/or preventing skin complexion imperfections.Type: ApplicationFiled: November 3, 2011Publication date: November 14, 2013Applicants: NESTEC S.A., L'OREALInventors: Audrey Gueniche, Isabelle Castiel
-
Publication number: 20130302454Abstract: A method for preparing fermentation broth of fruits and vegetables includes steps of mixing fruits, vegetables, bacteria liquid of Lactobacillus acidophilus, bacteria liquid of Bifidobactreium longum, bacteria liquid of Lactobacillus delbrueckii subsp. bulgaricus, and bacteria liquid of Streptococcus thermophilus, and processing fermentation to obtain the fermentation broth of fruits and vegetables. A fermenting course of the method could be controlled, and a fermenting period is reduced to 15 days.Type: ApplicationFiled: July 20, 2013Publication date: November 14, 2013Applicant: Jilin Zixin Pharmaceutical Research Institution LLC.Inventors: Dejun Sun, Jinlong Yin, Miaonan Sun, Yizhuo Zhao, Chunsheng Guo, Yanhui Gao, Xue Li
-
Publication number: 20130302342Abstract: The invention refers to a human lactoferrin derived peptide for use as an antigen masking agent in the production of a pharmaceutical composition for delivery of a biological active substance in a mammalian organism, where the biological active substance is able to induce an undesired immune response by the mammalian organism, where the pharmaceutical composition comprises a supramolecular aggregate of the biological active substance and the human lactoferrin derived peptide, with the effect that after delivery of pharmaceutical composition to the mammalian organism, there is no or only a diminished induction of the undesired immune response against the biological active substance.Type: ApplicationFiled: November 26, 2010Publication date: November 14, 2013Applicant: Evonik Roehm GmbHInventors: Benedikt Hartwig, Juan Tome Alcalde, Norbert Windhab, María del Pilar Ansuategui Panzano, Matías Javier Vara Carrera
-
Publication number: 20130302278Abstract: Improved (safer and more effective) methods of therapy using TNF-R agonists, e.g., CD40 agonists are provided. These methods provide for the addition of an amount of a type 1 interferon and/or a TLR agonist that is effective to prevent or reduce the toxicity (liver toxicity) that may otherwise result in some patients of the TNF-R agonist is used as a monotherapy (without the type 1 interferon and/or TLR agonist).Type: ApplicationFiled: April 16, 2013Publication date: November 14, 2013Inventors: Randolph J. Noelle, Ross M. Kedl, Cory L. Ahonen
-
Patent number: 8580321Abstract: The use of flagellin and flagellin related polypeptides for reducing cancer treatment side effects in mammals is described.Type: GrantFiled: February 11, 2009Date of Patent: November 12, 2013Assignee: The Cleveland Clinic FoundationInventors: Andrei V. Gudkov, Vadim Krivokrysenko, Lyudmila Burdelya
-
Publication number: 20130287874Abstract: The present invention relates to the field of spoonable yogurt compositions. In particular, the present invention provides spoonable yogurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may be bioactive heat treated probiotic micro-organisms, for example. The present invention also relates to health benefits provided by these non-replicating probiotic micro-organisms.Type: ApplicationFiled: November 10, 2011Publication date: October 31, 2013Applicant: NESTEC S.A.Inventors: Annick Mercenier, Guenolee Prioult, Sophie Nutten
-
Publication number: 20130280225Abstract: The present invention provides a composition that is suitable to reduce the impact of chronic stress on intestinal symptoms and/or conditions. The composition comprises a probiotic microorganism and soluble fiber. Preferably, the soluble fiber is a low viscosity soluble fiber. The composition is in particular suitable to alleviate abdominal discomfort, abdominal pain, abdominal cramps, and bowel movement disturbances; in as far as these conditions and symptoms are associated with stress.Type: ApplicationFiled: December 28, 2011Publication date: October 24, 2013Applicant: NESTEC S.A.Inventors: Magali Faure, Gabriela Bergonzelli Degonda
-
Publication number: 20130273186Abstract: Ophthalmic irrigating solutions are disclosed. The ophthalmic irrigating solution comprises: a) ?-polyglutamic acid (?-PGA) and/or salt thereof in an amount effective to increase the viscosity of the irrigating solution, and b) an ophthalmically acceptable aqueous vehicle for the ?-PGA and/or salt thereof. Also disclosed is a method of irrigating ocular tissues of a patient, in which the method comprises introducing to the ocular tissues of the patient an ophthalmic irrigating solution comprising ?-PGA) and/or salt thereof in an amount sufficient to irrigate the ocular tissues of the patient.Type: ApplicationFiled: June 16, 2013Publication date: October 17, 2013Inventors: Yu-Chun Chen, Wen-Yu Su, Yen-Hsien Lee, Ko-Hua Chen, Feng-Huei Lin
-
Publication number: 20130273187Abstract: The invention relates to methods of treating acne, which methods comprise topical administering to a skin of a subject in need thereof an effective amount of a lysate of Actinomyces, preferably strains R/3.88, L/1.89, or mixture thereof.Type: ApplicationFiled: December 19, 2011Publication date: October 17, 2013Inventor: Viktor Vladimirovich Redkin
-
Publication number: 20130273016Abstract: The present invention provides a composition that is suitable to reduce the impact of chronic stress on intestinal symptoms and/or conditions. The composition comprises a probiotic microorganism and soluble fiber. Preferably, the soluble fiber is a low viscosity soluble fiber. The composition is in particular suitable to alleviate abdominal discomfort, abdominal pain, abdominal cramps, and bowel movement disturbances; in as far as these conditions and symptoms are associated with stress.Type: ApplicationFiled: December 28, 2011Publication date: October 17, 2013Inventors: Magali Faure, Gabriela Bergonzelli Degonda
-
Publication number: 20130251770Abstract: Methods for reducing the appearance of wrinkles in a subject are provided herein. The methods of the present invention comprise identifying a wrinkle distribution on a subject and applying a topical composition comprising at least one chemodenervating agent onto and along the wrinkle distribution. The methods disclosed herein provide alternative methods for delivery of chemodenervating agents to the skin for the treatment of wrinkles.Type: ApplicationFiled: March 22, 2013Publication date: September 26, 2013Applicant: Revance Therapeutics, Inc.Inventors: Jacob M. Waugh, L. Daniel Browne
-
Publication number: 20130251695Abstract: The present application relates to the use of lactic acid-producing bacteria and the extracellular product thereof in cosmetic compositions.Type: ApplicationFiled: February 28, 2013Publication date: September 26, 2013Inventors: Sean Farmer, Michael A. Bush, David Keller, Andrew R. Lefkowitz
-
Publication number: 20130251829Abstract: A composition comprising a culture supernatant from a late-exponential growth phase of a batch-cultivation process for a probiotic such as LGG, for use in the treatment or prevention of infection by a pathogen such as C. sakazakki.Type: ApplicationFiled: March 15, 2013Publication date: September 26, 2013Applicant: MEAD JOHNSON NUTRITION COMPANYInventors: Eric A.F. van Tol, Gabriele Gross, Machtelt Braaksma, Karin M. Overkamp, Eduard K. Poels
-
Publication number: 20130251830Abstract: Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis.Type: ApplicationFiled: May 22, 2013Publication date: September 26, 2013Applicant: Allergan, Inc.Inventors: Aubrey N. Manack, Mitchell F. Brin
-
Publication number: 20130236581Abstract: The present invention relates to the field of frozen yoghurt. In particular, the present invention provides frozen yoghurt compositions comprising non-replicating probiotic micro-organisms. These non-replicating probiotic micro-organisms may bioactive heat treated probiotic micro-organisms, for example. The present inventions also relates to health benefits provided by these non-replicating probiotic micro-organisms.Type: ApplicationFiled: November 11, 2011Publication date: September 12, 2013Applicant: NESTEC S.A.Inventors: Annick Mercenier, Guenolee Prioult, Sophie Nutten
-
Patent number: 8529892Abstract: The present invention relates to methods for characterization of bacterial skin microbiota to provide diagnostic, therapeutic, and preventive measures for alleviating skin conditions. In certain embodiments, the invention relates to characterization of bacterial skin microbiota associated with psoriasis and related diagnostic, therapeutic, and preventive measures for alleviating psoriasis. These methods will be useful for detecting, diagnosing, and monitoring individuals who have or are at risk of certain skin conditions.Type: GrantFiled: February 24, 2011Date of Patent: September 10, 2013Assignee: New York UniversityInventors: Martin J. Blaser, Zhan Gao